Logo image of MAK.DE

MATERNUS-KLINIKEN AG (MAK.DE) Stock Fundamental Analysis

Europe - FRA:MAK - DE0006044001 - Common Stock

1.1 EUR
+0.03 (+2.8%)
Last: 10/17/2025, 7:00:00 PM
Fundamental Rating

1

Taking everything into account, MAK scores 1 out of 10 in our fundamental rating. MAK was compared to 31 industry peers in the Health Care Providers & Services industry. Both the profitability and financial health of MAK have multiple concerns. MAK is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

MAK had negative earnings in the past year.
In the past year MAK had a positive cash flow from operations.
In the past 5 years MAK always reported negative net income.
In the past 5 years MAK always reported a positive cash flow from operatings.
MAK.DE Yearly Net Income VS EBIT VS OCF VS FCFMAK.DE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10M -10M

1.2 Ratios

Looking at the Return On Assets, with a value of -9.59%, MAK is doing worse than 93.55% of the companies in the same industry.
Industry RankSector Rank
ROA -9.59%
ROE N/A
ROIC N/A
ROA(3y)-9.27%
ROA(5y)-6.94%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
MAK.DE Yearly ROA, ROE, ROICMAK.DE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20 -20 40 -40 60 -60

1.3 Margins

With an excellent Gross Margin value of 86.65%, MAK belongs to the best of the industry, outperforming 87.10% of the companies in the same industry.
MAK's Gross Margin has been stable in the last couple of years.
The Profit Margin and Operating Margin are not available for MAK so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 86.65%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.33%
GM growth 5Y0.95%
MAK.DE Yearly Profit, Operating, Gross MarginsMAK.DE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20 40 60 80

More info and screens

0

2. Health

2.1 Basic Checks

MAK does not have a ROIC to compare to the WACC, probably because it is not profitable.
MAK has about the same amout of shares outstanding than it did 1 year ago.
The number of shares outstanding for MAK remains at a similar level compared to 5 years ago.
MAK has a worse debt/assets ratio than last year.
MAK.DE Yearly Shares OutstandingMAK.DE Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M
MAK.DE Yearly Total Debt VS Total AssetsMAK.DE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M

2.2 Solvency

MAK has an Altman-Z score of -0.98. This is a bad value and indicates that MAK is not financially healthy and even has some risk of bankruptcy.
The Altman-Z score of MAK (-0.98) is worse than 83.87% of its industry peers.
MAK has a debt to FCF ratio of 19.09. This is a negative value and a sign of low solvency as MAK would need 19.09 years to pay back of all of its debts.
Looking at the Debt to FCF ratio, with a value of 19.09, MAK is doing worse than 74.19% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF 19.09
Altman-Z -0.98
ROIC/WACCN/A
WACC3.83%
MAK.DE Yearly LT Debt VS Equity VS FCFMAK.DE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M -50M 100M

2.3 Liquidity

A Current Ratio of 0.22 indicates that MAK may have some problems paying its short term obligations.
MAK has a worse Current ratio (0.22) than 90.32% of its industry peers.
MAK has a Quick Ratio of 0.22. This is a bad value and indicates that MAK is not financially healthy enough and could expect problems in meeting its short term obligations.
With a Quick ratio value of 0.21, MAK is not doing good in the industry: 90.32% of the companies in the same industry are doing better.
Industry RankSector Rank
Current Ratio 0.22
Quick Ratio 0.21
MAK.DE Yearly Current Assets VS Current LiabilitesMAK.DE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

More info and screens

1

3. Growth

3.1 Past

MAK shows a small growth in Earnings Per Share. In the last year, the EPS has grown by 7.72%.
Looking at the last year, MAK shows a quite strong growth in Revenue. The Revenue has grown by 11.43% in the last year.
MAK shows a decrease in Revenue. Measured over the last years, the Revenue has been decreasing by -1.73% yearly.
EPS 1Y (TTM)7.72%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-11.11%
Revenue 1Y (TTM)11.43%
Revenue growth 3Y0.76%
Revenue growth 5Y-1.73%
Sales Q2Q%3.79%

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
MAK.DE Yearly Revenue VS EstimatesMAK.DE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M
MAK.DE Yearly EPS VS EstimatesMAK.DE Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 -0.02 -0.04 -0.06

More info and screens

2

4. Valuation

4.1 Price/Earnings Ratio

MAK reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
MAK.DE Price Earnings VS Forward Price EarningsMAK.DE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0 0 0 0 0 0 0

4.2 Price Multiples

Based on the Enterprise Value to EBITDA ratio, MAK is valued more expensive than 80.65% of the companies in the same industry.
96.77% of the companies in the same industry are more expensive than MAK, based on the Price/Free Cash Flow ratio.
Industry RankSector Rank
P/FCF 2.35
EV/EBITDA 20.17
MAK.DE Per share dataMAK.DE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

No dividends for MAK!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

MATERNUS-KLINIKEN AG

FRA:MAK (10/17/2025, 7:00:00 PM)

1.1

+0.03 (+2.8%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Providers & Services
Earnings (Last)09-30 2025-09-30
Earnings (Next)N/A N/A
Inst OwnersN/A
Inst Owner ChangeN/A
Ins Owners81.7%
Ins Owner ChangeN/A
Market Cap23.07M
Analysts45.71
Price TargetN/A
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.2
P/FCF 2.35
P/OCF 2.33
P/B N/A
P/tB N/A
EV/EBITDA 20.17
EPS(TTM)-0.63
EYN/A
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)0.47
FCFY42.47%
OCF(TTM)0.47
OCFY42.88%
SpS5.44
BVpS-3.29
TBVpS-3.92
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -9.59%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 86.65%
FCFM 8.59%
ROA(3y)-9.27%
ROA(5y)-6.94%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.33%
GM growth 5Y0.95%
F-Score4
Asset Turnover0.83
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF 19.09
Debt/EBITDA 12.53
Cap/Depr 0.79%
Cap/Sales 0.08%
Interest Coverage N/A
Cash Conversion 102.07%
Profit Quality N/A
Current Ratio 0.22
Quick Ratio 0.21
Altman-Z -0.98
F-Score4
WACC3.83%
ROIC/WACCN/A
Cap/Depr(3y)22.85%
Cap/Depr(5y)18.44%
Cap/Sales(3y)2.27%
Cap/Sales(5y)1.84%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)7.72%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-11.11%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)11.43%
Revenue growth 3Y0.76%
Revenue growth 5Y-1.73%
Sales Q2Q%3.79%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y56.85%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y595.8%
FCF growth 3Y-3.29%
FCF growth 5Y-1.66%
OCF growth 1Y14887.9%
OCF growth 3Y-4.38%
OCF growth 5Y-1.22%